These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 9343794)

  • 1. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example.
    Hornberger JC; Best JH; Garrison LP
    Med Decis Making; 1997; 17(4):363-72. PubMed ID: 9343794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic evaluations: the special case of end-stage renal disease treatment.
    Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
    Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model.
    Douzdjian V; Ferrara D; Silvestri G
    Am J Kidney Dis; 1998 May; 31(5):794-802. PubMed ID: 9590189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of dialysis and kidney transplants in Japan.
    Kaminota M
    Keio J Med; 2001 Jun; 50(2):100-8. PubMed ID: 11450591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Implications of New National Allocation Policy for Deceased Donor Kidneys in the United States.
    Smith JM; Schnitzler MA; Gustafson SK; Salkowski NJ; Snyder JJ; Kasiske BL; Israni AK
    Transplantation; 2016 Apr; 100(4):879-85. PubMed ID: 26784114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.
    Chang RW; Pellisier JM; Hazen GB
    JAMA; 1996 Mar; 275(11):858-65. PubMed ID: 8596224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pediatric heart transplantation.
    Dayton JD; Kanter KR; Vincent RN; Mahle WT
    J Heart Lung Transplant; 2006 Apr; 25(4):409-15. PubMed ID: 16563970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis.
    Soohoo N; Schneider JA; Kaplan RM
    Med Decis Making; 1997; 17(2):193-8. PubMed ID: 9107615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation.
    Snyder RA; Moore DR; Moore DE
    Clin Transplant; 2013; 27(2):289-96. PubMed ID: 23350938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal transplantation vs hemodialysis: cost-effectiveness analysis.
    Perović S; Janković S
    Vojnosanit Pregl; 2009 Aug; 66(8):639-44. PubMed ID: 19780419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.
    Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC
    Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
    Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
    Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Controversies in nephrology: dialysis in the elderly].
    Ortega F; Gómez E; Baltar J; Rebollo P
    Nefrologia; 2001; 21(4):332-6. PubMed ID: 11816505
    [No Abstract]   [Full Text] [Related]  

  • 18. Costs associated with ventricular assist device use in children.
    Mahle WT; Ianucci G; Vincent RN; Kanter KR
    Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
    Manns B; Meltzer D; Taub K; Donaldson C
    Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.